JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Allakos to $10 from $11 and keeps an Outperform rating on the shares. The Phase 2b trials of lirentelimab in chronic spontaneous urticaria and atopic dermatitis are fully enrolled and remain on track for top-line data in late 4Q23/1Q24, the analyst tells investors in a research note. The firm continues to like lirentelimab’s positioning in the CSU pipeline with a differentiated mechanism of action, clean safety, and Phase 2a data suggesting a competitive efficacy profile.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALLK:
- Allakos price target lowered to $1.50 from $2.50 at Barclays
- Allakos files to sell $250M in common stock
- Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
- Allakos reports Q3 EPS (52c), consensus (45c)
- ALLK Upcoming Earnings Report: What to Expect?
Questions or Comments about the article? Write to editor@tipranks.com